Background: At the cellular level, Hematopoietic stem cells are the source of CML, and aberrant tyrosine kinase activity and clonal growth are caused by the BCR-ABL translocation. Antioxidant systems typically control the generation of ROS, but when they are dysregulated, disease progression occurs, underscoring their potential as therapeutic modulators.

Objective: To estimate the level of lipid peroxidation and micronutrients in chronic myeloid leukemia (CML) patients.

Methodology: Blood samples (5.0 ml) of 60 diagnosed chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKI’s) and blood samples (5.0 ml) of 50 healthy individuals as a control group was taken from vein in clotted gel vial from Oncology department, Mayo Hospital Lahore. Antioxidants, micronutrients, serum electrolytes and complete blood profile was examined.

Results: serum malondildehyde (MDA) level in CML patients was 4.32 ± 0.61mM while in healthy individuals, it was 0.75 ± 0.51mM which reveal that serum malondildehyde (MDA) level was elevated significantly (p = 0.000) in CML patients as compared to control group. vitamin A level in disease persons was 0.39 ± 0.06 μg/mL and in control group, it was 1.98 ± 0.29 μg/mL which point out that Vitamin A in disease persons was lower significantly (p = 0.001) as compared to control group. Serum vitamin C level in CML patients was 0.34 ± 0.28 μg/mL and in healthy individuals it was 1.50 ± 0.65 μg/mL.

Conclusion: Present study concluded that lipid peroxidation level increased in CML patients due to which serum MDA level was also increased while serum micronutrients level declined while oxidative stress level declined in patients treated with drugs

Keywords:CML; Antioxidants; Imatinib; TKI’s; Micronutrients

References

1. Arsalan HM., et al. “Prospective biochemical analysis of chronic myeloid leukemia patients in response to tyrosine kinase inhibitors”. Pakistan Journal of Zoology5 (2023): 2103-2111.
2. Massimino M., et al. “Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia”. Molecular Cancer1 (2018): 56.
3. Hochhaus A., et al. The New England Journal of Medicine10 (2017): 917.
4. Arsalan HM., et al. “Tracking Molecular Response of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia Patients Using RT-PCR Profiling of BCR-ABL Transcripts”. Chelonian Conservation and Biology2 (2023): 1174-1186.
5. Kalmanti L., et al. “Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV”. Annals of Hematology1 (2014): 71-80.
6. Irwin ME., et al. “A NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignancies”. Oncotarget 27 (2001): 23631.
7. Faiza M., et al. “Pre and post treatment effect of imatinib and anti-oxidant status in chronic myeloid leukemia Patients”. Journal of Population therapeutics & Clinical Pharmacology 5 (2024): 1391-1401.
8. Hughes TP and Shanmuganathan N. “Management of TKI-resistant chronic phase CML”. Hematology 1 (2022): 129-137.
9. Kantarjian HM., et al. “Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis”. Cancer 97 (2003): 1033-1041.
10. Lavallade HD., et al. “Imatinib for Newly Diagnosed Patients with Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis”. Journal Of Clinical Oncology Original Report20 (2008).
11. Goldman JM. “Treatment strategies for CML. & Research”. Clinical Haematology 22 (2009): 303-313.
12. Loscocco F., et al. “BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia”. Frontiers in Oncology 9 (2019): 939.
13. Jiye A., et al. “Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses”. PLoS ONE10 (2010): 13186.
14. Gladwin MT and Wang X. “Methodological vexation about thiol oxidation versus S-nitrosation-a commentary on “An ascorbate-dependent artifact that interferes with the interpretation of the biotin switch assay”. Free Radical Biology and Medicine4 (2006): 557-561.
15. Spitz DR and Oberley LW. “Measurement of Mn-SOD and Cu-Zn-SOD activity in mammalian tissue homogenates”. Current Protocol Toxicology 8 (2001): 7.5.1-7.5.11.
16. Weydert JC and Cullen JJ. “Measurement of Superoxide Dismutase, Catalase and Glutathione Peroxidase in cultured cells and tissue”. Nature Protocols1 (2011): 51-66.
17. Khazaal MS., et al. “Association of BCR/ ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients”. Molecular Genetics and Genomic Medicine 7 (2019): e809.
18. Kim TD., et al. “Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib”. Leukemia 6 (2013): 1316-1321.
19. Geelen IG., et al. “Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects”. Annals of Hematology 6 (2023): 1395-1408.
20. Bilajac E., et al. “Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines”. Metabolites 11 (2022): 58.
21. Dong C., et al. “Oxidative stress in leukemia and antioxidant treatment”. Chinese Medical Journal 16 (2021): 1897-1907.
22. Ahmed AA., et al. “Chronic Myeloid Leukemia: A retrospective study of clinical and pathological features”. Bionatura3 (2022): 41.
23. Donne DI., et al. “Protein carbonylation, cellular dysfunction, and disease progression”. Journal of Cellular and Molecular Medicine 2 (2006): 389-406.
24. Ren X., et al. “Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors”. Annals of Hematology 98 (2019): 1627-1640.
25. Kuan JW., et al. “The epidemiology of chronic myeloid leukaemia in southern Sarawak, Borneo Island”. Medical Journal of Malaysia 73 (2018): 78-85.

Citation

Citation: Ali Waheed Goraya., et al. “Assessment of Lipid Peroxidation and Micronutrients Level in Chronic Myeloid Leukemia Patients from Punjab Pakistan".Acta Scientific Cancer Biology 9.4 (2025): 03-10.

Copyright

Copyright: © 2025 Ali Waheed Goraya., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.